Uva Ursi for Urinary Tract Health

Research suggests that uva ursi (bearberry) shows some potential for supporting urinary tract health, primarily through its active compound arbutin, which is converted in the body into hydroquinone and concentrated in the urinary tract where it may exert antibacterial effects, though the clinical evidence is decidedly mixed. Several randomized controlled trials comparing uva ursi to antibiotics found that while it meaningfully reduced antibiotic use — with one 2021 trial reporting roughly 64% fewer antibiotic courses — women using the herb experienced greater symptom burden and, in that same trial, a higher rate of kidney infections compared to those receiving standard antibiotic treatment, raising notable safety considerations. Safety-focused studies, including a 2013 review of free hydroquinone exposure and a 2018 cell study examining arbutin's effects on lymphocytes, suggest the compound is relatively low in toxicity at recommended doses, though a 2022 laboratory study found that hydroquinone can induce oxidative stress in bladder cells even at therapeutic concentrations, indicating that the full safety picture remains incompletely understood. Overall, the body of evidence — which includes multiple RCTs, a Cochrane meta-analysis focused on related non-antibiotic approaches, and several mechanistic and safety studies — does not yet support uva ursi as a reliable replacement for antibiotic therapy in urinary tract infections, and individuals considering it should weigh the potential reduction in antibiotic exposure against the documented possibility of slower symptom relief and more serious complications.